Acromegaly with normal growth hormone levels: response to sandostatin-LAR treatment

Pituitary

Volumn 2, Issue 4, 2000, Pages 289-294

  Shimon, Ilan ^a   Nass, Dvora ^a   Hadani, Moshe ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Acromegaly; Growth hormone; IGF I; Pituitary adenoma; Somatostatin

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HUMAN GROWTH HORMONE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ADENOMA; ADULT; ARTICLE; BLOOD; CASE REPORT; DRUG EFFECT; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; VISION;

ACROMEGALY; ADENOMA; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; HUMAN GROWTH HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; OCTREOTIDE; PITUITARY NEOPLASMS; PROLACTIN; VISION;

EID: 0034180344     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Shimon I, Melmed S. Growth hormone- and growth-hormone-releasing hormone-producing tumors. In: Arnold A (ed). Endocrine Neoplasms (Cancer Treatment and Research Series). Kluwer Academic Publishers, 1997;1-24.
2. Hartman ML, Veldhuis JD, Vance ML, Faria AC, Furlanetto RW, Thorner MO. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab 1990;70:1375-1384.
3. Melmed S. Acromegaly. N Engl J Med 1990;322:966-977.
4. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood KE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979;301:1138-1142.
5. Chang-DeMoranville BM, Jackson IM. Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am 1992;21:649-668.
6. Brockmeier SJ, Buchfelder M, Adams EF, Schott W, Fahlbusch R. Acromegaly with normal serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery. Harm Metab Res 1992;24:392-400.
7. Pagesy P, Li JY, Kujas M, Peillon F, Delalande O, Visot A, Derome P. Apparently silent somatotroph adenomas. Pathol Res Pract 1991;187:950-956.
8. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, DeMont Friberg R, Chandler WF, Sandler HM. Pituitary irradiation is ineffective in normalization plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187-3191.
9. Lindholm J, Giwercman B, Giwercman A, Astrup J, Bierre P, Skakkebaek NE. Investigation of the criteria for assessing the outcome of treatment in acromegaly. Clin Endocrinol (Oxf) 1987;27:553-562.
10. Stewart PM, Kane FK, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analogs (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267-3272.
11. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Burns Ch, Jervell J. Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab 1997;81:23-28.
12. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release Lanreotide. J Clin Endocrinol Metab 1997;81:18-22.
13. Lamberts SWJ. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endoc Rev 1988;9:417-436.
14. Flyvberg A, Jorgensen KD, Marshall SM, Orskov H. Inhibitory effect of octreotide on growth-hormone induced IGF-1 generation and ovarian growth in the hypophysectomized rats. Am J Physiol 1991;260:568-574.
15. Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: A potential pituitary independent mechanism for action. J Clin Endocrinol Metab 1992;75:1459-1463.